Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D. Redfield RR, et al. Among authors: tremblay s. Am J Transplant. 2019 Nov;19(11):3035-3045. doi: 10.1111/ajt.15514. Epub 2019 Jul 23. Am J Transplant. 2019. PMID: 31257724 Free PMC article. Clinical Trial.
Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR, Vinks AA, Fukuda T, Mizuno T, King EC, Zou Y, Jiang W, Woodle ES, Tremblay S, Klawitter J, Klawitter J, Christians U. Alloway RR, et al. Among authors: tremblay s. PLoS Med. 2017 Nov 14;14(11):e1002428. doi: 10.1371/journal.pmed.1002428. eCollection 2017 Nov. PLoS Med. 2017. PMID: 29135993 Free PMC article. Clinical Trial.
A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease.
Abu Jawdeh BG, Woodle ES, Leino AD, Brailey P, Tremblay S, Dorst T, Abdallah MH, Govil A, Byczkowski D, Misra H, Abuchowski A, Alloway RR. Abu Jawdeh BG, et al. Among authors: tremblay s. Clin Transplant. 2018 Jan;32(1). doi: 10.1111/ctr.13155. Epub 2017 Dec 4. Clin Transplant. 2018. PMID: 29140548 Clinical Trial.
mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
Castro-Rojas CM, Godarova A, Shi T, Hummel SA, Shields A, Tremblay S, Alloway RR, Jordan MB, Woodle ES, Hildeman DA. Castro-Rojas CM, et al. Among authors: tremblay s. Transplantation. 2020 May;104(5):1058-1069. doi: 10.1097/TP.0000000000002917. Transplantation. 2020. PMID: 31415033 Free PMC article. Clinical Trial.
375 results